<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145947</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-BC502</org_study_id>
    <nct_id>NCT04145947</nct_id>
  </id_info>
  <brief_title>Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients</brief_title>
  <official_title>Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients Via Analysis of Immunoinflammation-related Protein Complexes in Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The relationship between immune inflammation-related protein complexes in blood of triple
      negative breast cancer patients and recurrence or metastasis of breast cancer will be
      studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      200 patients with triple negative breast cancer will be followed up. Peripheral venous blood
      was collected every 3 to 6 months. Change regularity of breast cancer-specific immune
      inflammation-related protein complexes in blood at different follow-up time points will be
      studied. The relationship between disease-specific protein complexes and pathological state
      of patients will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>immune inflammation-related protein complexes</measure>
    <time_frame>2 years</time_frame>
    <description>The change of immune inflammation-related protein complexes which is measured by gel permeation chromatography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood markers</measure>
    <time_frame>2 years</time_frame>
    <description>The expression of CA153, CEA, CA125 in the blood of the patients, which are measured by electro-chemiluminescence immunoassay.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>triple negative breast cancer</arm_group_label>
    <description>triple negative breast cancer patients with age ≤ 60 years old</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1 mL of blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        triple negative breast cancer patients with age ≤ 60 years old
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Postoperative pathology confirmed invasive breast cancer after surgery for breast lump

          -  Breast cancer-related chemotherapy and radiotherapy completed

          -  triple negative breast cancer patients

          -  age ≤ 60 years old

        Exclusion Criteria:

          -  Male

          -  Aged above 60

          -  Breast Carcinoma in situ

          -  Women in pregnancy or breastfeeding

          -  Suffering from other malignant tumors

          -  Non-compliant patient
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The participant eligibility is based on the physiological sex.</gender_description>
    <minimum_age>36 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi Shen</last_name>
    <phone>+86-18611768360</phone>
    <email>shenxisx@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Shen</last_name>
      <phone>+86-18611768360</phone>
      <email>shenxisx@sohu.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Xi Shen</investigator_full_name>
    <investigator_title>Attending doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

